The Exchange had sought clarification from Sun Pharmaceutical Industries with respect to news article appearing in Reuters Website on September 10, 2015 titled ‘Sun Pharma looking to divest Ireland plant’. Sun Pharmaceutical Industries replied stating that they hereby confirm that following Sun Pharmas successful completion of Ranbaxy merger, there is an opportunity to optimize overall manufacturing network. As a result, decisions are being made by the Company / the Company subsidiary companies to either close or divest some of the Company’s/subsidiaries manufacturing facilities respectively. Currently, the Ireland facility has been identified for divestment. Whenever the divestment process for this facility is complete, statutory disclosures, as may be required, will be made. They further state that such proposed divestment has no/would have no material impact on Company’s performance, operations or revenues.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1887.95 |
| Dr. Reddys Labs. | 1348.70 |
| Cipla | 1431.65 |
| Zydus Lifesciences | 1149.00 |
| Lupin | 2457.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: